Browse C5 Companies

4th Advanced Forum on

Biotech Patents

The Tactical and Practical Guide to Today's Most Complex Issues

Monday, December 06, 2004

About

In the ongoing quest to develop new, effective and profitable biological products and therapies, the biotech and pharmaceutical industries are constantly and aggressively fighting to preserve and enforce their patent rights to the existing tools and processes which continue to enable them to unlock the secrets of genetic defects and disease.

However, innovator biotech companies are now about to face a whole new set of patent challenges. The patent life cycles of many of their most lucrative biological products are on the verge of expiration. Generic competitors are seeking to put biogenerics on the market in a manner similar to that of small molecule generic drugs. Although it is anyone's guess as to what the final outcome of these latest patent challenges will be, one thing is certain: based on the number of infringement suits filed in the last year alone, these companies will hold no bars to protect the patents on their biotech inventions.

With millions in future revenue at stake, it is imperative that counsel to biotech and pharmaceutical companies and their advisors have an up-to-the-minute and complete understanding of the latest legal developments affecting biotech patents. This American Conference Institute publication will give you in-depth analysis from an outstanding faculty of leading in-house biotech and pharmaceutical counsel and expert attorneys.

Contents & Contributors

About

In the ongoing quest to develop new, effective and profitable biological products and therapies, the biotech and pharmaceutical industries are constantly and aggressively fighting to preserve and enforce their patent rights to the existing tools and processes which continue to enable them to unlock the secrets of genetic defects and disease.

However, innovator biotech companies are now about to face a whole new set of patent challenges. The patent life cycles of many of their most lucrative biological products are on the verge of expiration. Generic competitors are seeking to put biogenerics on the market in a manner similar to that of small molecule generic drugs. Although it is anyone's guess as to what the final outcome of these latest patent challenges will be, one thing is certain: based on the number of infringement suits filed in the last year alone, these companies will hold no bars to protect the patents on their biotech inventions.

With millions in future revenue at stake, it is imperative that counsel to biotech and pharmaceutical companies and their advisors have an up-to-the-minute and complete understanding of the latest legal developments affecting biotech patents. This American Conference Institute publication will give you in-depth analysis from an outstanding faculty of leading in-house biotech and pharmaceutical counsel and expert attorneys.

Contents & Contributors

THE SCOPE OF PROTECTION UNDER THE "SAFE HARBOR" PROVISION OF THE HATCH-WAXMAN ACT AND THAT OF FOREIGN COUNTERPARTS; APPLICABILITY OF THE "SAFE HARBOR" PROVISION TO RESEARCH TOOL PATENTS; AND SECTION 271(g) AND THE IMPORTATION OF DATA
Brian D. Coggio, Orrick, Herrington & Sutcliffe LLP